Arvinas Inc ARVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
-
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
-
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
-
Arvinas to Participate in Upcoming Investor Conferences
-
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Trading Information
- Previous Close Price
- $6.97
- Day Range
- $6.95–7.15
- 52-Week Range
- $6.74–14.35
- Bid/Ask
- $7.03 / $7.10
- Shares Outstanding
- 65.39M
- Market Cap
- $462.93M
- Volume/Avg
- 141,383 / 793,702
Key Statistics
- Price/Earnings (Normalized)
- 52.29
- Price/Sales
- 1.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 20.16%
Company Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 246
- Website
- https://www.arvinas.com
Valuation
|
Metric
|
ARVN
|
|---|---|
Price/Earnings (Normalized) | 52.29 |
Price/Book Value | 0.81 |
Price/Sales | 1.48 |
Price/Cash Flow | 10.15 |
Price/Earnings
ARVN
Financial Strength
|
Metric
|
ARVN
|
|---|---|
Quick Ratio | 7.54 |
Current Ratio | 7.91 |
Interest Coverage | — |
Quick Ratio
ARVN
Profitability
|
Metric
|
ARVN
|
|---|---|
Return on Assets (Normalized) | 5.68% |
Return on Equity (Normalized) | 8.43% |
Return on Invested Capital (Normalized) | 3.27% |
Return on Assets
ARVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|l#&J?P | LOCK|>BC> | $127B | |||
| Moderna Inc
MRNA
| LOCK|P><%sf | LOCK|dy | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@&RJD^% | LOCK|hY$> | $81B | |||
| argenx SE ADR
ARGX
| LOCK|<Q%>P& | LOCK|?D | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|T@><#vq | LOCK|@H | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|lGYwW& | LOCK|Hq&c | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|YS!BD%& | LOCK|?>tm | $27B | |||
| Incyte Corp
INCY
| LOCK|&ZSs&T | LOCK|Fv | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|mtn^&M | LOCK|RH< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HqJ@@&% | LOCK|Hvz | $14B |
United States